Teligent Recalls Five Additional Lots of Lidocaine Topical Solution
October 12, 2021Lupin Pharmaceuticals Recalls All Irbesartan and Irbesartan/HCTZ
October 14, 2021October 13, 2021 – Verzenio® (abemaciclib) is now approved as an adjuvant treatment for HR-positive, HER2-negative, node-positive early breast cancer in adults who are at high risk of disease recurrence following surgery. Under this indication, patients must have a Ki-67 score of ≥ 20%, and Verzenio should be administered in combination with endocrine therapy (tamoxifen or an aromatase inhibitor).
- Ki-67 is a marker of cell growth. The higher the Ki-67 score, the more quickly cells are dividing to form new cells. In breast cancer, a Ki-67 score of more than 20% is considered high and may be an indicator of faster-growing, more aggressive disease.
- Verzenio first received FDA approval in 2017 and has three additional indications for the treatment of HR-positive, HER2-negative breast cancer.
- Recommended dosing under the newest indication is 150mg twice daily until completion of two years of treatment, or until disease recurrence or unacceptable toxicity occur. Verzenio is an oral tablet manufactured by Eli Lilly.